Clinical Impact of Automatic Implantable Cardioverter Defibrillators (AICD) Compared to Medication Therapy on Patients with Dilated Cardiomyopathy at Sakon Nakhon Hospital.
Article Sidebar
Main Article Content
Abstract
Background: Dilated Cardiomyopathy (DCM) is a major cause of sudden cardiac death (SCD) worldwide. The use of automatic implantable cardioverter defibrillator (AICD) may reduce the risk of SCD. However, its clinical benefits in non-ischemic patients re-main unclear. This study aims to compare clinical outcomes between standard medical therapy and AICD combined with medical therapy in patients with Non-ischemic DCM.
Methods: This retrospective descriptive study analyzed medical records of 120 patients treated at Sakon Nakhon Hospital from January 1st, 2017, to December 31st, 2022. Patients were divided into two groups AICD combined with medical therapy (n=60) and medical therapy alone (n=60). Data were analyzed using descriptive statistics and survival analysis.
Results: The SCD rate was significantly lower in the AICD group (2.3%) compared to the medical therapy group (6.8%) (p = 0.0405). However, no significant difference was observed in overall survival (OS) between the two groups (p = 0.1599) Additional-ly, treatment with an Automatic Implantable Cardioverter Defibrillator (AICD) does not affect the functional status of the heart as assessed by the New York Heart Association Functional Classification (NYHA FC).
Conclusion: AICD combined with medical therapy significantly reduces the SCD rate in patients with Non-ischemic DCM compared to medical therapy alone. However, it does not improve overall survival.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Reichart D, Magnussen C, Zeller T, Blankenberg S. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: A translational review of current literature. J Intern Med. 2019;286(4):362-72. doi: 10.1111/joim.12944.
Merlo M, Gigli M, Poli S, Stolfo D, Brun F, Lardieri G, et al. Dilated cardiomyopathy: a dynamic disease - clinical course, reverse remodeling and prognostic stratification. G Ital Cardiol (Rome). 2016;17(1):15-23. doi: 10.1714/2140.23184.
Behnoush AH, Khalaji A, Naderi N, Ashraf H, von Haehling S. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Fail. 2023;10(3):1531-44. doi: 10.1002/ehf2.14255.
Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55. doi: 10.1136/bmj.f55.
Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52. doi: 10.1186/1471-2261-13-52.
Priori SG, Blomström-Lundqvist C. 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J. 2015;36(41):2757-9. doi: 10.1093/eurheartj/ehv445.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. doi: 10.1056/NEJMoa013474.
Betensky BP, Dixit S. Sudden cardiac death in patients with nonischemic cardiomyopathy. Indian Heart J. 2014;66 Suppl 1(Suppl 1):S35-45. doi: 10.1016/j.ihj.2013.12.047.
Gutman SJ, Costello BT, Papapostolou S, Voskoboinik A, Iles L, Ja J, et al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J. 2019;40(6):542-50. doi: 10.1093/eurheartj/ehy437.
Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221-30. doi: 10.1056/NEJMoa1608029.
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012.
Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453-8. doi: 10.1161/01.cir.0000012350.99718.ad.
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-8. doi: 10.1056/NEJMoa033088.
Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol. 2003;41(10):1707-12. doi: 10.1016/s0735-1097(03)00297-3.